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Abstract
Introduction and objective. Mast cells (MC) are effector cells during severe systemic reactions (SR) to Hymenoptera stings. 
Venom specific immunotherapy (VIT) is the treatment of choice for prevention of SR to stings. Tryptase and prostaglandin D2 
metabolites (PGD2) are the markers of MC activation. The study design was to 1. compare baseline values of serum tryptase 
concentration (BST) and PGD2 metabolites in children with/without venom sensitization, 2. to evaluate an influence of rush 
VIT on MC markers in treated children.  
Materials and methods. Sensitized group: 25 children with SR to Hymenoptera sting. Control group: 19 healthy children. 
Active treatment: 5-day-rush-VIT. BST was evaluated by ImmunoCAP, PGD2 metabolites in blood and urine by GC-NICI-MS. 
Results. The baseline blood levels of MC markers were significantly higher, while urinary concentration of 9α,11β-PGF2 was 
significantly lower in the whole group of venom-sensitized children compared to controls. Severity of SR showed negative 
correlation with urinary PGD2 metabolites, while positive with plasma 9α,11β-PGF2 and BST concentration The highest 
sensitivity was obtained for plasma 9α,11β-PGF2 whereas the highest specificity for urinary PGD-M.  
Conclusions. In children with IgE-mediated SR to Hymenoptera stings, elevation of baseline values of PGD2 metabolites in 
blood is accompanied by decreased excretion of its urinary metabolites.  
Assessment of stable PGD2 metabolites might serve as an independent MC marker to identify allergic children.  
There is an association between urinary PGD2 metabolites and severity of the SR to Hymenoptera stings.
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INTRODUCTION
Venom allergy is an example of an acute hypersensitivity 
reaction, a type of systemic reaction that occurs in less 
than 1% of the children population, and which are usually 
less severe than in adults. In children with the history of 
life-threatening venom-triggered systemic IgE-mediated 
reactions, a 3- to 5-year course of subcutaneous specific 
venom immunotherapy (VIT) is a treatment of choice, even 
at age below 5 years, providing 98% rate of long-lasting 
protection against a subsequent sting [1,2]. Most studies 
concerning risk factors and mechanism of both venom 
allergy and immunoprotection following treatment have 
been conducted in adults [3]. It is not possible to extrapolate 
directly these results to children [4].
Systemic reactions (SR) due to Hymenoptera stings are 
mainly initiated by the IgE-mediated release of mediators from 
mast cells and basophils upon exposure to venom allergens. 
Despite the progress in diagnostic methods of IgE-mediated 
mechanisms of sting allergy, effector cells of anaphylaxis 
still remain the target of many studies in venom allergy [5]. 
Demonstration of rapid, transient increase of serum tryptase 
level (enzymatically active mature β-tryptase) after specific 
allergen stimulation reflects massive mast cell activation 
and confirms the diagnosis of anaphylaxis [6] while baseline 
serum mast cell tryptase (BST) (inactive α,β-protryptases) 
concentration reflects the constitutive, individual mast cell 
load or activity. Values higher than 11.4 ng/mL are considered 
to be a marker of mast cell clonal disorders, including occult 
systemic mastocytosis  [7]. Two recently published large 
cohort, multicenter studies allowed for the construction of 
a model/ identification of the characteristic risk factors of 
severe systemic reaction after Hymenoptera field stings as 
well as during the buildup phase of VIT in adults [8, 9]. BST 
elevated above 5.84 ng/mL is among the identified predictors. 
There are some data on increase of BST with age, which might 
explain aggravated sting allergic reactions in elderly people 
[10]. Prostaglandin D2 is a major cyclooxygenase product 
released by activated mast cells. It is unstable and metabolized 
by NADPH-dependent 11-ketoreductase to 9α,11β-PGF2, 
which is further transformed by oxidation to tetranor-PGD-M 
(PGD-M), both being rapidly excreted in urine [11, 12]. These 
early indicators of mast cell activation, were found to be 
useful in monitoring asthmatic adults [13, 14, 15] and children 
[16, 17]. Urinary concentration of 9α,11β-PGF2 proved to be a 
reliable marker of endogenous production of inflammatory 
mediators associated with anaphylaxis [18].
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Objective. In our previous study we attempted to estimate the 
role of BST, as well as both blood and urinary prostaglandin 
D2 metabolites, in predicting systemic side reaction during 
Hymenoptera venom immunotherapy in children [19]. In 
this study we wanted to compare the baseline values of 
prostaglandin D2 metabolites and serum tryptase between 
symptomatic venom sensitized and healthy children, as 
well as to estimate the impact of rush schedule of venom 
immunotherapy on these parameters. There are no such 
studies in children.
MATERIALS AND METHOD
Study subjects. Sample of this prospective case-control 
study comprised two groups: a venom-sensitized group and 
a healthy control group. Venom-sensitized group included 
twenty five children (20 boys) aged 6–17 years (mean 11.5; 
SD 3.5;) fulfilling both inclusion criteria of 1. Systemic 
(grade II-IV according to Mueller’s classification) reaction 
to Hymenoptera sting, children with the history of grade II of 
systemic reaction were qualified to VIT in case of increased 
exposure to stings (e.g. bee keepers families). 2. IgE-mediated 
venom allergy which was confirmed by positive result of at 
least one of the following procedures: a skin prick tests with 
venom extract concentration 100mcg/ml, intradermal tests 
with up-dosing to maximum concentration 1 mcg/ml, and 
specific serum IgE estimation by ImmunoCAP (Phadia AB, 
Uppsala, Sweden) were performed three to six weeks after 
systemic sting reaction. The venom extract used to skin 
testing as well as to treatment was obtained from the same 
manufacturer. Atopy was confirmed by positive skin prick 
test to inhalant allergens (Allergopharma Joachim Ganzer 
KG). After obtaining the results of diagnostic procedures 
venom-sensitized children were randomly divided into 
two groups of in-patient treatment: nineteen children 
(10 sensitized to Apis m. venom, 9 sensitized to Vespula spp. 
venom) to 5-day rush VIT with Venomenhal (HALAllergy, 
The Netherlands) (cumulative dose equal to 216.46 mcg), and 
6 children (sensitized to Apis m. venom) to 5-day rush VIT 
with Pharmalgen (ALK Abello, Denmark) (cumulative dose 
equal to 223.3 mcg). The difference in cumulative dose was 
negligible. There is a common source (Vespa Laboratories, 
Penn, USA) of venom used by both manufacturers to 
produce the aqueous venom extract. The schedule of VIT 
was concordant with manufacturers’ instruction. No 
antihistamines, systemic glucocorticosteroids, or LTRA 
were administered during VIT. On each VIT treatment day 
patients were examined for symptoms of respiratory tract 
infection, stable clinical status and PEF over 80% of normal 
value. Systemic side-reactions (SSR) during treatment were 
monitored.
Control group consisted of nineteen children enrolled 
from hospital out-patients’ rehabilitation department, aged 
7–11 years (mean age 9.1; SD 1.5; 8 boys) who fulfilled the 
following criteria: 1. Negative history of personal/family atopic 
diseases, no allergic sting reactions or autoimmunological 
disorders in phone administered interview with the parents 
of the child, 2. No atopic symptoms or urticaria pigmentosa 
on physical examination, 3. Negative skin prick tests with 
common inhalant allergens, milk and egg food allergens 
(Allergopharma Joachim Ganzer KG), negative serum specific 
IgE to Apis m. and Vespula spp. venoms
An informed consent to participate in the study was 
obtained from parents of the study subjects. The study 
protocol was approved by Jagiellonian University Ethical 
Committee.
COLLECTION Of SAMpLES
In the treated group, samples of fasting venous blood and 
morning urine were taken twice for estimation of the mast 
cell biomarkers: 1. at baseline, before first dose of rush VIT, 2. 
after the last injection of incremental dose – for 9α,11β-PGF2 
measurment blood was collected 5 minutes after injection of 
the venom extract, and one hour later for tryptase estimation. 
Urine sample was collected within 1–2 hours after the last 
injection. In the control group blood and urine samples 
were taken once to estimate basal serum tryptase level, 
plasma 9α,11β-PGF2 and the first morning urine sample 
metabolite content. Time schedule of samples collection 
reflected metabolism of both mediators and was in line with 
other authors [12, 14].
Blood samples. for tryptase were allowed to clot, then 
centrifuged and serum stored at –80 °C. Fluoroenzyme 
immunoassay method using CAP System (Phadia, Uppsala, 
Sweden), which estimates both pro-forms and mature 
β tryptase, was performed. Serum tryptase detection ranges 
within 1–200 ng/mL, while values below are considered 
normal 10 ng/mL [20]. In case of values over 10 ng/mL 
we performed duplicate measurements. According to 
manufacturer, the inter-assay variability for tryptase levels 
is below 5% for the range between 1.0 and 100 ng/mL. 
Anticoagulated blood samples (citrate) for 9α,11β-PGF2 were 
immediately centrifuged at 3500 rpm for 10 minutes and 
500 pg deuterium labelled prostaglandin F2α ([2H4] PGF2α) as 
an internal deuterated standard (Cayman Chemicals, Ann 
Arbor, Mi, USA) was added to 1 ml plasma. To 0,2 ml of urine 
samples internal deuterated standards of prostaglandin F2α 
([2H4] PGF2α) and PGD-M ([2H6] tetranor-PGD-M) was also 
added. This compensated for analytes lost during sample 
preparations. All samples were stored at –80 °C and assayed 
within one month. Measurement of 9α,11β-PGF2 and 
PGD-M were performed using gas chromatography negative-
ion chemical ionization mass spectrometry (GC-NICI-MS) 
(model 5896 series II; Hewlett Packard,Palo Alto,CA,USA) 
as described elsewhere [12, 13, 21]. The diagnostic ions were 
569 m/z for 9α,11β-PGF2 and 573 m/z for internal standard, 
while for PGD-M m/z 489 and m/z 495, respectively, where 
m/z denotes a mass-to-charge ratio: the quantity formed by 
dividing the mass of an ion by the unified atomic mass unit 
and by its charge number (positive absolute value)[22]. For 
plasma samples the detection limit was 1 pg/mL, while for 
urinary samples 0,5 ng/mg creatinine. The concentration for 
plasma samples was expressed in picogram per milliliter, for 
urinary samples in nanogram per milligram of creatinine.
Statistical analysis. Descriptive statistics were expressed as 
median (Me) and quartiles (Q1-Q3). Comparison of variables 
measured at two time points was done with Wilcoxon signed-
rank test. For variables measured at the same time point 
comparison between two groups was done with Mann-
Whitney test, while for more than two groups with Kruskal-
Wallis test. Strength of relationship between variables was 
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estimated with Kendall tau-b coefficient. General Linear 
Model (GLM) was used to adjust the influence of age on 
PGD-M level in relationship to other parameters. The 
predictive value of PGD2 metabolites and BST for venom 
allergy was estimated using a receiver operator characteristics 
(ROC) curve for each PGD2 metabolite and BST separately. 
The cut point for the best sensitivity-to-specificity ratio was 
reported [23]. An area under the ROC curve (AUC) which is 
not significantly different from 0.5 means that prediction of 
venom allergy using the marker is no better than a result due 
to chance. As the study was not of cross-sectional design, the 
positive (or negative) predictive values, defined as percentages 
of cases among positive results of test (or percentage of 
non-cases among negative results of test, respectively), 
were computed based on assumption that prevalence of 
venom allergy in general children population equals 0.5 
(different authors report values ranging from 0.3 to 0.8) 
using formulas depending on sensitivity and specificity of the 
markers [24, 25, 26]. Differences were regarded statistically 
significant at 0.05 type I error level. Analysis were done using 
SPSS 15 for Windows.
RESULTS
Characteristics of the treated group. The patients’ mean age 
was higher in Apis m.venom sensitized children. In Vespula 
spp. sensitized children no one had the history of anaphylactic 
shock after a sting. Four patients were atopic, two with 
clinical manifestation of controlled mild bronchial asthma, 
in two symptoms of perennial allergic rhinitis were present. 
Regarding standard diagnostic procedures total IgE level was 
significantly higher in venom allergic children in comparison 
to controls (p=0.001). In children sensitized to Apis m., the 
absolute values of venom specific IgE were higher than values 
of specific IgE in those sensitized to Vespula spp. (Tab. 1).
Baseline prostaglandin D2 metabolites and tryptase in 
children sensitized to Hymenoptera venom and control 
group. Gender and atopy did not influence the baseline level 
of mast cell biomarkers, while age showed significant negative 
correlation with urinary PGD-M at baseline (tau-b=–0.40, 
p=0.007).
In the whole group of children sensitized to Hymenoptera 
the baseline values of both mast cell markers in blood were 
significantly higher (p=0,025 for tryptase, and p<0,001 
for 9α,11β-PGF2, respectively), while baseline urinary 
concentration of 9α,11β-PGF2 significantly lower (p<0,001) 
in comparison to the control group (Tab. 2).
Regarding the type of sensitization, the baseline urinary 
PGD-M concentration was the highest in the control group, 
while the lowest in Apis m.-sensitized group (p=0.011). The 
serum tryptase level did not differ in this comparison (Fig. 1). 
After adjustment for age, the difference in PGD-M urinary 
level between treated groups and controls was still significant 
(p=0.049). Both plasma and urinary concentration of 9α,11β-
PGF2 retained their significance of difference (p=0.001 and 
p=0.002, respectively) as well.
A comparison within venom allergic children revealed 
higher urinary PGD-M concentration in Vespula sensitized 
than in Apis m. sensitized children (p=0.02) (Tab. 2). After 
adjustment for age, the difference lost its significance 
(p=0,101).
For the whole group of venom allergic children Mueller’s 
grade of systemic reaction after sting showed negative 
correlation with both urinary 9α,11β-PGF2 and PGD-M 
concentrations at baseline. The median concentration of 
urinary PGD-M significantly decreased with the increase 
of Mueller’s grade score (from 5.21 (3.94–10.23) ng/mg 
creatinine for the patients with grade II, to 2.12 (0.73–4.97) 
for the patients with grade III, and to 1.33 (0.43–2.86) for 
the patients with grade IV) (p=0.043). After adjustment for 
age, relationship between Mueller’s grade score and PGD-M 
concentration was still significant (p=0.001). Regarding 
the type of sensitization, it was still significant in Vespula 
sensitized group (p=0.035), while it lost its significance 
in Apis m. group (p=0.087) (Fig 2). The median value of 
urinary 9α,11β-PGF2 concentration was the highest (1,60 
(1.10–3.19)) in patients with grade II reaction, the lowest 
(0.58 (0.34–1.10)) in patients with the history of grade III 
sting reaction, while intermediate (0.65 (0.57–2.39)) in 
patients with the history of anaphylactic shock (grade IV) 
(p=0.012). There was no correlation between Mueller’s grade 
score and any mast cell mediators in plasma. A correlation 
coefficient between baseline both plasma and urinary 9α,11β-
PGF2 concentration was significantly negative (tau-b=–0.30, 
p=0.034) in the whole group of allergic children. Regarding 
the type of sensitization this correlation remained significant 
only in Vespula sensitized children (tau-b=–0.67, p=0.012) 
but not in Apis m. sensitized group (tau-b=–0.11, p=0.558). 
No correlation between mast cell metabolites was detectable 
in the control group.
Effects of venom immunotherapy on prostaglandin D2 
metabolites and serum tryptase in sensitized children. 
VIT caused a significant increase of serum tryptase, but not 
in PGD2 metabolites in the whole treated group. Further 
analysis revealed, however, that increase of serum tryptase 
was significant for whole treated group (from 3.23 (2.41–5.06) 
to 3.63 (2.96–4.97) ng/mL; p=0.003) and Apis m. allergic 
children (from 3.34 (2.26–4.59) to 3.88 (2.99–4.83) ng/mL; 
p=0.010) (Fig. 1).
Table 1. Characteristics of VIT treated and control groups
Apis m. VIT 
group
Vespid 
VIT group
control 
group
Total
N 16 9 19 44
Gender: boys (%) 12 (75%) 8 (89%) 8 (42%) 28 (64%)
Age: mean ± SD 12.4±3.0 9.9±3.9 9±1.5 10.4±3.1
Mueller’s classification grade
IIo
IIIo
IVo
7 (44%)
6 (38%)
3 (18%)
4 (44%)
5 (56%)
0
11 (44%)
11 (44%)
 3 (12%)
Presence of atopy 3 (18%) 1 (11%)  4 (16%)
total IgE: Me (Q1-Q3) (kU/l)
137.5 
(67.2–229.0)
91.8 (1.5–
307.5)
16.4 
(8.1–30.5)
Vespid serum venom specific 
IgE: Me (Q1-Q3) (kU/l)
0.5 (0.0–1.1)
2.3 
(1.1–18.1)
0.00
Apis m. serum venom specific 
IgE: Me (Q1-Q3) (kU/l)
21.1 
(8.5–46.9)
0.0 
(0.0–0.4)
0.00
Positive results of IDT 11 (69%) 5 (56%) NP
Positive results of SPT 0 (0%) 0 (0%) NP
IDT – intradermal tests, NP – not performed, SPT – skin prick tests, Me – median value, Q1 –25th 
percentile, Q3 –75th percentile
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figure 3. Receiver-operating (ROC) characteristics for blood and urinary mast cell markers
figure 1. Change in mast cell markers concentration during induction phase of VIT with reference to type of 
venom sensitization, in comparison to healthy controls
figure 2. Relationship between Mueller’s grade and mast cell markers concentration with reference to type of 
venom sensitization
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The relative increase of serum tryptase concentration in 
reference to the baseline value (relative delta bound) ranged 
from 88% to 158%. In four patients a relative increase ≥ 135% 
of the BST was observed, in one patient it was close to this 
bound. In spite that fact, immunotherapy was well tolerated, 
none of treated patients demonstrated systemic side effects 
during 5-day rush VIT.
There was no significant difference between baseline and 
post treatmentVIT values in PGD2 metabolite concentration. 
However, regardless the type of venom sensitization both 
plasma and urinary median concentration decreased, while 
PGD-M median concentration increased during induction 
phase treatment (Fig. 1).
Serum tryptase at baseline, correlated positively with its 
level after treatment in whole treated group (tau-b=0.79, 
p<0.001), and in subgroups analyzed for the type of 
sensitization (tau-b=0.78, p=0.004 and tau-b=0.83, p<0.001 
in Vespula spp and Apis m. sensitized group, respectively). 
Urinary 9α,11β-PGF2 concentration after treatment correlated 
positively with its basal level only in Apis m. venom treated 
children (tau-b=0.48, p=0.010), while PGD-M pre/after VIT 
concentration correlated negatively in Vespula spp treated 
children (tau-b=–0.56, p=0.037).
Predictive properties of the markers to distinguish venom 
allergic children from controls. Baseline concentrations 
of both blood markers and urine 9α,11β-PGF2, evaluated 
using ROC curve, revealed the potency to discriminate 
between venom allergic children and controls (Figure 3). 
The area under the curve for those three markers reached 
at least 0.7, being significantly different from value of 0.5, 
what reflects probability of random assignment of patient as 
allergic. The highest value of AUC and the optimal sensitivity/
specifity ratio (for cut point of 1,67 ng/mg creatinine) in case 
of urinary 9α,11β-PGF2 was achieved. Positive predictive 
values estimated for analyzed markers were all lower than 
1.5% reaching 1.0% for tryptase and plasma 9α,11β-PGF2. 
Negative predictive values were estimated as higher than 
99.6% reaching 99.9% for both plasma and urine 9α,11β-
PGF2 (Tab. 3).
DISCUSSION
The reasons why some cases develop allergic reactions from 
bee and wasp stings, while others do not, still remains a 
mystery. An answers to this question is being searched for from 
among a variety of possible influences, such as environmental 
factors on allergy, as well as in more sophisticated fields, like 
genetic aspects of venom allergy or evaluation of effector cells 
(mast cells and basophils) markers [27, 28, 29]. Our case-
control study represents the first – and novel – attempt to 
compare the baseline values of prostaglandin D2 metabolites 
and serum tryptase between symptomatic venom sensitized 
and healthy children. We investigated also how 5-day venom 
specific rush VIT influences these parameters.
All Hymenoptera venom sensitized children were 
diagnosed in line with EAACI and AAAAI guidelines 
[1,  30,  31]. To achieve reliable laboratory results all drugs 
which may interfere with clinical symptoms (NSAID, LTRAs, 
antihistamines and systemic glucocorticosteroids) were 
withdrawn [32].
We did not find differences in level of mast cell markers 
between genders in venom allergic children, what might be 
due to the predominance of boys in the study group, which 
was also reported by other authors [33, 34]. In our study, the 
age of children showed a negative correlation with urinary 
PGD-M levels, but not with the other mast cell mediators, 
which is similar to the results obtained by Kielbasa et al. in 
their study on eicosanoids measurements in exhaled breath 
condensate of asthmatic children after provocation test [16]. 
Considering the type of venom sensitization and adjustment 
for the age of subjects, especially 9α,11β-PGF2 concentration 
in both biological fluids behaved more stable than urinary 
PGD-M or serum tryptase concentration, thus indicating 
that 9α,11β-PGF2, a PGD2 metabolite, might provide better 
discriminating of venom allergic children from controls.
In venom sensitized children none of mast cell mediators 
measured in blood at baseline had discriminating power 
Table 2. Comparison of baseline median values (and interquartile ranges) of analyzed parameters between whole venom allergic group, regarding 
the type of venom sensitivity and control group
serum tryptase
(ng/mL)
plasma 9α,11β-
PGF2 (pg/ mL)
urinary 9α,11β-
PGF2 (ng/mg 
creatinine)
urinary PGD-M
(ng/mg creatinine)
Vespula spp. allergic group 3.21 (2.43–8.03) 23.72 (14.03–47.85) 0.88 (0.37–2.20) 4.97 (4.26–9.68)
Apis melifera allergic group 3.34 (2.26–4.59) 52.52 (27.28–70.05) 1.10 (0.57–1.60) 1.54 (0.72–5.17)
whole group of venom allergic children 3.23 (2.41–5.06) 37.70 (22.52–62.00) 1.10 (0.54–2.12) 3.94 (1.26–6.61)
Control group 2.18 (1.75–3.29) 13.32 (4.70–28.60) 2.50 (1.74–3.47) 6.31 (3.08–9.26)
Comparison between whole venom allergic group and control group p=0.025 p=0.001 p< 0.001 p=0.095
Comparison between Vespula spp and Apis melifera venom allergic children and controls p=0.077 p=0.001 p= 0.002 p=0.011
Comparison between Vespula spp and Apis melifera venom allergic children groups p=0.637 p=0.084 p=1.000 p=0.020
Table 3. Utility of the mast cell markers in indicating venom 
hypersensitivity
Baseline 
serum 
tryptase
Plasma
9α,11β-
PGF2
Urinary 
9α,11β-
PGF2
Urinary
PGD-M
AUC 0.70 0.80 0.81 0.65
p for difference between AUC 
and 0.5
0.025 0.001 <0.001 0.095
Sensitivity 0.64 0.88 0.79 0.58
Specificity 0.68 0.58 0.72 0.76
Cut point
Unit of measurement
2.57
ng/mL
15.57
pg/mL
1.67
ng/mg 
creatinine
6.06
ng/mg 
creatinine
Positive predictive value 1.0 1.0 1.4 1.2
Negative predictive value 99.7 99.9 99.9 99.7
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to distinguish between the type of sensitizing venom or 
severity of past anaphylactic reaction. An observation of the 
lower blood concentration of mast cell mediators in venom 
allergic children, as well as, the higher concentration in 
urine in control group, is consistent with the measurements 
results in which both urinary PGD2 metabolites revealed the 
negative association with Mueller’s grade in case of whole 
group of venom allergic children, as well as separately, in 
Vespula spp. allergic children. Hence, indicating that higher 
baseline values of urinary PGD2 metabolites can discriminate 
not only sensitized children from healthy ones, but also 
might be useful in indicating those with milder systemic 
reaction. It is in line with the results of our previous study, 
in which we described the higher urinary 9α,11β-PGF2 
concentration in children without severe SR to VIT in 
comparison to patients with severe SR [19]. We speculate 
that higher urinary excretion may reflect some protective 
mechanisms. The similar phenomenon – of higher PGD2 
metabolites values in milder symptoms – was observed by 
Bochenek et al. in asthmatic patients stratified by severity of 
disease [14]. It is tempting to speculate that in severe systemic 
reactions to Hymenoptera stings, catabolism of PGD2 to its 
inactive metabolites does not accelerate in response to its 
higher systemic biosynthesis.
We observed significant difference in baseline values 
of serum tryptase between venom allergic children and 
controls (3.23 ng/mL vs. 2.18 ng/mL). The similar data were 
reported by Yavuz in the age and sex-matched sample of 
Turkish children with insect venom allergy, showing that 
median level of BST in children with insect sting systemic 
reaction was significantly higher than in children with large 
local reaction and healthy subjects (4.2 vs 3.1 vs. 2.9 ng/mL, 
respectively) [35]. On the other hand in Komarow’s paper on 
197 children (age range: 6 months to 18 years) there was no 
statistically significant difference between non-atopic and 
atopic subjects (3.44 vs 3.56 ng/mL); though venom allergy 
was not included into study group [36].
During 5-day rush venom specific immunotherapy with 
aqueous venom extract none of patients demonstrated 
systemic side effects (non-reactors). In our study, the median 
value of BST were equal to 3.21 ng/mL for Vespula spp. allergic 
group and to 3.34 ng/mL for Apis m allergic group, which 
are below the median value 4.25 ng/mL from the cohort 
multicenter study, in which odds ratio of severe systemic 
reaction after sting in adults increased markedly when BST 
concentration was higher than 5 ng/mL [8]. In our recent 
study, we noted that children sensitized to Apis m. venom 
with mean value of serum tryptase level exceeding 7.75 ng/mL 
were at risk for systemic reaction to venom injection during 
rush protocol [19]. Other authors also reported that total 
tryptase level could indicate a risk for systemic reactions 
to rush immunotherapy and mast cell activation [37, 38]. 
Estimating the response to VIT, in comparison pre/post 
rush VIT values of mast cell mediators, only serum tryptase 
level, increased significantly, though within normal range, 
in the whole treated group and in Apis m. allergic subgroup. 
This is in line with the results pointing out that especially 
incremental phase of immunotherapy with bee venom extract 
goes together with the higher risk of systemic side effects 
and so this phase of treatment requires special attention 
[39]. Some authors pointed to an association between 
hypersensitivity reaction in adult venom allergic patients 
and a relative increase of serum tryptase level to ≥ 135% 
of the baseline value [40]. In our study, only four of twenty 
five patients had this parameter exceed that limit. As none 
of our patients had reaction to venom extract, data from 
more patients will be necessary to validate this finding. The 
schedule of samples collection in our study did not allow 
us to estimate the circadian rhythm of mast cells mediators 
concentration in children [41].
In contrast to BST compared during pre/post rush VIT, 
PGD2 metabolites concentrations were stable, with non-
significant decrease of 9α,11β-PGF2 both plasma and urinary 
concentration and non-significant increase of PGD-M, which 
may reflect observed safety of both rush-VIT protocol and 
venom extract used in treatment. In addition to the abundant 
PGD-M, a tetranor end product of oxidation, used in our 
study [42], a new eicosanoid-derived urinary biomarker 
2,3-dinor-9α,11β-PGF2 emerged as the useful for monitoring 
symptomatic anaphylaxis and aspirin–intolerant asthma 
[43, 44]. Authors suggested that it might be the most reliable 
indicator in determining PGD2 production in vivo, thus 
indicating that PGD2 metabolites are mediators of special 
interest in studies dedicated to allergy.
At baseline, the plasma levels of PGD2 metabolite were 
elevated, while urinary PGD2 metabolites were decreased, 
discriminating venom allergic children from control group. 
Analysis of ROC curve properties showed acceptable 
parameters for all markers except urinary PGD-M, for which 
areas under curve were significantly higher that value of 0.5, 
reflecting probability of random assignment of the patient 
as venom-allergic or not. Among these three parameters, 
however, only for plasma 9α,11β-PGF2 the ROC curve does 
not intersects the reference line, indicating it as even better 
marker of venom hypersensitivity than BST. This suggests 
that for a very low level of tryptase and for a very high level 
of urinary 9α,11β-PGF2, these markers may wrongly classify 
healthy children as venom allergic ones, and vice versa. This 
may be due to the fact that control group in this study was 
smaller in size than the allergic one, what may underrepresent 
number of healthy children with the lowest values of BST. 
This might lead to situation that the smallest level of tryptase 
were observed in allergic children, although when comparing 
allergic and control group, the second one had significantly 
lower level of BST. Extended number of subjects in future 
studies are necessary to validate here reported observations. 
Though mast cells are the main effector cells of anaphylaxis 
in comparison to basophils, an attempts to evaluate venom 
allergy with basophil markers, are much more advanced in 
comparison to PGD2 metabolites, originating exclusively 
from mast cells. Basophil activation test (BAT) has been 
introduced in both diagnosis and VIT monitoring of venom 
allergic patients [45, 46, 47, 48]. There are also attempts to 
introduce it as an useful diagnostic tool in IgE-negative 
patients with the history of systemic sting reaction [49]. 
The first, very interesting data on blood basophils as a target 
for VIT, indicated for impaired release of both preformed 
and newly generated mediators during 3,5-hours lasting 
ultra-rush VIT protocol [50]. Just recently preliminary data 
on simultaneous evaluation of BAT and mast cell markers 
during first 40 days of VIT introduction (build-up phase and 
two maintenance doses) was published recently. Authors 
concluded that plasma levels of 9α,11β-PGF2 decrease while 
numbers of activated basophils increase during the initial 
phase of bee venom rush immunotherapy in children [51].
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CONCLUSIONS
Children with history of IgE-mediated systemic reaction 
to Hymenoptera stings are characterized by elevated 
baseline values of mast cell metabolites in blood, and by 
decreased urinary PGD2 stable metabolite concentration, 
that discriminates them from non-allergic children. Thus, 
assessment of the stable urinary PGD2 metabolite might serve 
as an independent marker of mast cell activation in these 
patients. There is a negative association between urinary 
PGD2 metabolites and severity of the systemic reactions. 
Uneventful rush venom therapy is not associated with any 
changes in either plasma or urinary levels of PGD2 stable 
metabolites.
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